Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. Versiani, M Journal of affective disorders, 51(3):323--332, December, 1998. ![Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex Chronic depression was once considered untreatable pharmacologically. Open studies conducted around 1980 demonstrated efficacious results with tricyclics, classical MAOIs and lithium in 45% of cases. The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD.10, facilitated controlled trials in subjects with “pure dysthymia” and those with superimposed major depression (so-called “double-depression”). TCAs, SSRIs, RIMA, and benzamides have all proven effective in an average of 65% vs. an average of 25% with placebo. Well tolerated compounds–e.g. moclobemide, sertraline and desipramine–may permit the long-term clinical management of this spectrum of dysthymic and related conditions. Patients with “lifetime pure dysthymia” tend to respond more slowly to antidepressants than those with concurrent major depression (“double-depression”) or those with “pure dysthymia” but with history of major depressive episodes. Chronicity is now well established: indeed discontinuation of antidepressants in a 4-year maintenance study has resulted in 89% rate of relapse. Dysthymia is a disabling condition and high doses of antidepressants are needed to achieve full recovery.
@article{versiani_pharmacotherapy_1998,
title = {Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide},
volume = {51},
issn = {0165-0327},
url = {http://www.ncbi.nlm.nih.gov/pubmed/10333986},
abstract = {Chronic depression was once considered untreatable pharmacologically. Open studies conducted around 1980 demonstrated efficacious results with tricyclics, classical MAOIs and lithium in 45\% of cases. The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD.10, facilitated controlled trials in subjects with “pure dysthymia” and those with superimposed major depression (so-called “double-depression”). TCAs, SSRIs, RIMA, and benzamides have all proven effective in an average of 65\% vs. an average of 25\% with placebo. Well tolerated compounds–e.g. moclobemide, sertraline and desipramine–may permit the long-term clinical management of this spectrum of dysthymic and related conditions. Patients with “lifetime pure dysthymia” tend to respond more slowly to antidepressants than those with concurrent major depression (“double-depression”) or those with “pure dysthymia” but with history of major depressive episodes. Chronicity is now well established: indeed discontinuation of antidepressants in a 4-year maintenance study has resulted in 89\% rate of relapse. Dysthymia is a disabling condition and high doses of antidepressants are needed to achieve full recovery.},
language = {en},
number = {3},
journal = {Journal of affective disorders},
author = {Versiani, M},
month = dec,
year = {1998},
pmid = {10333986},
keywords = {Mental Health/Care: Pathogensis},
pages = {323--332}
}
Downloads: 0
{"_id":"hysQc3YYbebN6H3kW","bibbaseid":"versiani-pharmacotherapyofdysthymicandchronicdepressivedisordersoverviewwithfocusonmoclobemide-1998","downloads":0,"creationDate":"2018-03-15T15:56:59.290Z","title":"Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide","author_short":["Versiani, M"],"year":1998,"bibtype":"article","biburl":"http://bibbase.org/zotero/davidlloyd3","bibdata":{"bibtype":"article","type":"article","title":"Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide","volume":"51","issn":"0165-0327","url":"http://www.ncbi.nlm.nih.gov/pubmed/10333986","abstract":"Chronic depression was once considered untreatable pharmacologically. Open studies conducted around 1980 demonstrated efficacious results with tricyclics, classical MAOIs and lithium in 45% of cases. The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD.10, facilitated controlled trials in subjects with “pure dysthymia” and those with superimposed major depression (so-called “double-depression”). TCAs, SSRIs, RIMA, and benzamides have all proven effective in an average of 65% vs. an average of 25% with placebo. Well tolerated compounds–e.g. moclobemide, sertraline and desipramine–may permit the long-term clinical management of this spectrum of dysthymic and related conditions. Patients with “lifetime pure dysthymia” tend to respond more slowly to antidepressants than those with concurrent major depression (“double-depression”) or those with “pure dysthymia” but with history of major depressive episodes. Chronicity is now well established: indeed discontinuation of antidepressants in a 4-year maintenance study has resulted in 89% rate of relapse. Dysthymia is a disabling condition and high doses of antidepressants are needed to achieve full recovery.","language":"en","number":"3","journal":"Journal of affective disorders","author":[{"propositions":[],"lastnames":["Versiani"],"firstnames":["M"],"suffixes":[]}],"month":"December","year":"1998","pmid":"10333986","keywords":"Mental Health/Care: Pathogensis","pages":"323--332","bibtex":"@article{versiani_pharmacotherapy_1998,\n\ttitle = {Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide},\n\tvolume = {51},\n\tissn = {0165-0327},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/10333986},\n\tabstract = {Chronic depression was once considered untreatable pharmacologically. Open studies conducted around 1980 demonstrated efficacious results with tricyclics, classical MAOIs and lithium in 45\\% of cases. The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD.10, facilitated controlled trials in subjects with “pure dysthymia” and those with superimposed major depression (so-called “double-depression”). TCAs, SSRIs, RIMA, and benzamides have all proven effective in an average of 65\\% vs. an average of 25\\% with placebo. Well tolerated compounds–e.g. moclobemide, sertraline and desipramine–may permit the long-term clinical management of this spectrum of dysthymic and related conditions. Patients with “lifetime pure dysthymia” tend to respond more slowly to antidepressants than those with concurrent major depression (“double-depression”) or those with “pure dysthymia” but with history of major depressive episodes. Chronicity is now well established: indeed discontinuation of antidepressants in a 4-year maintenance study has resulted in 89\\% rate of relapse. Dysthymia is a disabling condition and high doses of antidepressants are needed to achieve full recovery.},\n\tlanguage = {en},\n\tnumber = {3},\n\tjournal = {Journal of affective disorders},\n\tauthor = {Versiani, M},\n\tmonth = dec,\n\tyear = {1998},\n\tpmid = {10333986},\n\tkeywords = {Mental Health/Care: Pathogensis},\n\tpages = {323--332}\n}\n\n","author_short":["Versiani, M"],"key":"versiani_pharmacotherapy_1998","id":"versiani_pharmacotherapy_1998","bibbaseid":"versiani-pharmacotherapyofdysthymicandchronicdepressivedisordersoverviewwithfocusonmoclobemide-1998","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/10333986"},"keyword":["Mental Health/Care: Pathogensis"],"downloads":0},"search_terms":["pharmacotherapy","dysthymic","chronic","depressive","disorders","overview","focus","moclobemide","versiani"],"keywords":["mental health/care: pathogensis"],"authorIDs":[],"dataSources":["kRLSZGSDAgwZPh2tM"]}